Core Insights - The article discusses the upcoming data release from Rezolute's phase 3 sunRIZE study, expected in the second half of 2025, which is a significant milestone for the company [2]. Group 1 - Rezolute is preparing for the release of critical data from its late-stage clinical trial, which could impact its market position and investor interest [2]. - The author of the article operates the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and includes a model portfolio of small and mid-cap stocks [2].